SCHEMBL2803590

SCHEMBL2803590

Cc1ccnc(NC(=N)Nc2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.49
▸ NPC1 O15118 6/20 0.49
▸ SMN1; SMN2 Q16637 5/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.47
▸ PKM P14618 3/20 0.46
▸ TP53 P04637 2/20 0.46
▸ LMNA P02545 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ FASN P49327 1/20 0.44
▸ CCNE1 P24864 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ GBA1 P04062 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5923305 0.91 SMN1; SMN2 (0.45) RAB9ANPC1SMN1; SMN2KMT2APOLB
SCHEMBL5923222 0.88 NPSR1 (0.49) RAB9ANPC1SMN1; SMN2KMT2APOLB
SCHEMBL5923080 0.85 RAB9A (0.48) RAB9ANPC1SMN1; SMN2KMT2APOLB
SCHEMBL5923480 0.85 RAB9A (0.58) RAB9ANPC1SMN1; SMN2KMT2APOLB
SCHEMBL5923230 0.81 SMN1; SMN2 (0.50) RAB9ANPC1SMN1; SMN2KMT2APOLB
SCHEMBL5923526 0.81 MAPK1 (0.57) RAB9ANPC1SMN1; SMN2KMT2APOLB
SCHEMBL5923608 0.78 LMNA (0.48) RAB9ANPC1SMN1; SMN2KMT2APOLB
SCHEMBL5923337 0.78 SCN9A (0.51) RAB9ANPC1KMT2APOLBLMNA
SCHEMBL9395369 0.77 KDR (0.52) —
SCHEMBL5923038 0.77 POLB (0.42) RAB9ANPC1SMN1; SMN2KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296697-B2 Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors ABBOTT LABORATORIES (US) 2016-03-29 — — US disclosed
US-20100184787-A1 Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184787-A1 Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors HTR5A, HTR2C, HTR1E RAB9A 1031/4885NPC1 2234/4885SMN1; SMN2 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback